dissemination – Page 58 – Communicable Diseases Research

SAMHD1 as the Potential Link Between SARS-CoV-2 Infection and Neurological Complications

Neurology

Published on 2020-09-252022-11-01
Journal: Frontiers in Neurology [Category] COVID-19,

Protective Behavior in Course of the COVID-19 Outbreak—Survey Results From Germany

Public Health

Published on 2020-09-242022-10-31
Journal: Frontiers in Public Health [Category] COVID-19, MERS, SARS,

[키워드] 95%CI age Behavior being build changes in Characteristics Contact COVID-19 COVID-19 knowledge COVID-19 outbreak cross-sectional survey daily practice dissemination educational inequalities Factor female Frequency Gender Germany Health Behavior Health Education higher odd hygiene infected with COVID-19 infection control information knowledge less logistic regression model Measures nine Odds ratio outcomes pandemic participated predictor Protective reduce Result risk Seven Sex Social inequalities socio-demographic sociodemografics factors Spread Strategy the disease wearing face mask were used
[DOI] 10.3389/fpubh.2020.572561 PMC 바로가기 [Article Type] Public Health

Data-driven modeling for different stages of pandemic response

Article

Published on 2020-09-212022-10-28
Journal: ArXiv [Category] COVID-19,

[키워드] aligning changes complex country COVID-19 COVID-19 pandemic Critical data set dataset datasets disease dissemination driving effort Factor Factors increasingly Outbreaks outcomes pandemic Pandemics Perspective question Region risk Spread Stage Support the disease
PMC 바로가기 [Article Type] Article

Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark

Letter

Published on 2020-09-172022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour Administered administration age All participant allergy anti-cytokine therapy approved asked Bacterial infection BCG BCG vaccination blinded to treatment block Bone marrow Chemotherapy component Controlled trial COVID-19 COVID-19 pandemic criteria cumulative current daily dose Day defined Denmark Direct dissemination dose Effect element eligible ENhance EudraCT excluded exclusion group HCW Health care Health care worker HIV-1 hospital Hospital admission hospitals Human immunodeficiency virus Immunocompromised immunodeficiency incidence Inclusion infected with SARS-CoV-2 Infection infections Infectious disease injection Intervention intravenous lymphoma malignancy Medicine meet morbidity and mortality mycobacterial Mycobacterium tuberculosis NaCl solution non-specific not blinded number participant physician Placebo Prednisone Prevent protective effect protocol random randomisation randomised randomised controlled trial receive recruit reduce reductions in Registered reported resuspended Sample secondary Serious Adverse Event severity of COVID-19 Sex solid organ transplantation steroid Stratification study participant Study protocol subject subjects susceptibility suspicion Treatment Trial Tuberculosis Vaccine Vaccines website
[DOI] 10.1186/s13063-020-04714-3 PMC 바로가기 [Article Type] Letter

Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-162022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Administered administration Admission age allergy anti-IL6 anti-IL6 inhibitor antibody approved ARDS assigned AST/ALT authority baseline Blinding block Blood Brescia caused changed clinical clinical follow-up Clinical practice clinical trial concealed conducted consequence control arm control group Corticosteroids COVID COVID-19 COVID-19 infected patient COVID-19 infected patients COVID-19 patients CRP cytokine release death dissemination dose early intervention early treatment eCRF effective Efficacy and safety element elements elevated End end point EudraCT evaluate Evidence experimental arm Face mask Final Follow-up hospital Hospitalized hospitalized patients hyperinflammation Hyperinflammatory syndrome hypersensitivity Hypothesis ICU ICU admission IL-6 IL6 immunosuppressive in some inflammatory markers inflammatory parameter inhibitor initial Injury interstitial pneumonia Intervention lactation LDH life-threatening Local lymphopenia mechanical ventilation Methylprednisolone multi organ failure nasal neutropenia Non-invasive number objective open label Open-label outcome Oxygen requirement Parallel Arm participant pathogen Patient patients performed Pneumonia positive RT-PCR Pregnancy PROC produced progression proportion protocol protocols provided pulmonary infiltrate Radiographic randomised randomised controlled trial randomization Randomly RCT receive Registration reported rescued Respiratory failure risk risk factor Sample size sarilumab SARS-CoV SARS-CoV-2 SAS Sepsis Serum ferritin severe COVID-19 severe COVID-19 disease severe interstitial pneumonia severe respiratory failure Spain Spanish SpO2 Standard Standard of care study drug Study protocol supplemental oxygen therapeutic therapeutic intervention therapy Treatment treatment arm Treatment outcome Trial ULN use of corticosteroid Viral pneumonia virus website worsening
[DOI] 10.1186/s13063-020-04633-3 PMC 바로가기 [Article Type] Letter

COVID-19: Retransmission of official communications in an emerging pandemic

Research Article

Published on 2020-09-162022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] Affect agency amplification Analysis automated changes in coding combating Compliance condition COVID-19 Critical decrease develop dissemination events feature Features finding Guidance Health identify message pandemic platform precursor Protective regression modeling Research risk shown social media
[DOI] 10.1371/journal.pone.0238491 PMC 바로가기 [Article Type] Research Article

Mobile Health Apps on COVID-19 Launched in the Early Days of the Pandemic: Content Analysis and Review

Original Paper

Published on 2020-09-162022-10-31
Journal: JMIR mHealth and uHealth [Category] COVID-19,

COVID-19 Associated With Life-Threatening Apnea in an Infant Born Preterm: A Case Report

Pediatrics

Published on 2020-09-152022-10-31
Journal: Frontiers in Pediatrics [Category] COVID-19,

Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneumonia from COVID-19: A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-09-152022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Adverse reaction age allergy Anti-inflammatory Antibody test anticipated antiviral therapy assigned Bandar Abba Bandar Abbas Blinding Breastfeeding C-reactive protein Chest computed tomography chronic heart disease clinical clinical study clinical symptom Clinical symptoms clinical trial company conducted Confirmed Control control group Corticosteroids COVID-19 criteria Critical diagnosis of SARS-CoV-2 Diseases disorders dissemination diuretics dose drugs dry cough education Effect element evaluated feature Features female patient Fever glycyrrhiza history hospital Hospitalization hypertension ill patient incidence Infection inhibitor intervention group Iran Laboratory Laboratory signs licorice liquorice liver lymphocytopenia male Medical Sciences Ministry of Health Moderate COVID-19 number objective Open-label outcome parallel-group participant Patient pharmaceutical Placebo Pneumonia polymerase chain Primary outcome protocol random randomization randomize Randomized Randomized controlled trial regimen Registered registry renal Sample size screened secondary outcome selective serotonin reuptake inhibitor Seven single-center standard treatment status Study protocol therapeutic Thyroid time tiredness Treatment treatment arm Trial university Version website X-ray
[DOI] 10.1186/s13063-020-04706-3 PMC 바로가기 [Article Type] Letter

A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-142022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] administration age antiviral therapy approved asked assumption blind blinded carried Chemical Chemotherapy clinical clinical trial COVID COVID-19 COVID-19 patient COVID-19 positive patients Cytokine analysis cytokine profile determine dissemination edentulous Effectiveness element eligibility assessment excluded expected explained female FIVE Flow gargles Glasgow coma score group hospitalised hydrogen hypertonic identify IFN-γ IL-10 IL-2 IL-4 IL-6 Immunological test Inc. inclusion criteria Intervention Intubated Karachi Laboratory laboratory-confirmed lesion male Mild moderate disease mucosal nasal Nasal lavage number objective outcome parallel group participant Patient PCR test positive controls Primary outcome product protocol provided Purposive sampling quantitative PCR Radiotherapy randomised randomised controlled trial real time reducing reduction in Registered reported Research Research question salivary Sample size sealed Standard status study group Study protocol subject Symptoms the patient TNF-α treated Trial unit university university hospital Viral load website
[DOI] 10.1186/s13063-020-04634-2 PMC 바로가기 [Article Type] Letter